From Mechanism to Human Outcome: Why Translation Fails
The short answer
A plausible mechanism is the beginning of a research programme, not its conclusion. Translation requires the right material to reach the right tissue, engage the intended target at a tolerable exposure, change relevant biology and ultimately improve an outcome that matters in people.
Failure can occur at any link. Strong activity in a purified assay does not guarantee cellular exposure; target engagement does not guarantee disease modification; and a biomarker change does not guarantee clinical benefit.
Mechanistic plausibility
Mechanistic studies ask whether a material binds a target or changes a pathway under defined conditions. They can establish a causal chain within the model when supported by controls such as target knockout, antagonism, rescue experiments or orthogonal measurements.
Biology contains parallel pathways, feedback loops and compensatory responses. A target can be real while still being insufficient to change a complex disease or whole-organism outcome.
Potency is not exposure
Potency describes the concentration associated with an effect in a particular assay. In a living organism, absorption, protein binding, enzymatic degradation, distribution, barriers and clearance determine whether a relevant unbound concentration reaches the target tissue.
A highly potent material with poor tissue exposure may fail, while increasing exposure can create off-target effects or toxicity elsewhere.
Target engagement and downstream biology
Researchers should distinguish detection of the material, evidence of target engagement, a proximal pathway change, a downstream biomarker and a functional outcome. These are different evidentiary steps.
If target engagement is never demonstrated, a negative result may reflect inadequate exposure. If engagement occurs without a meaningful outcome, the biological hypothesis, endpoint or population may be wrong or incomplete.
Species and model differences
Animals can differ from humans in receptor sequence, tissue distribution, metabolism, immune responses and disease biology. Experimental models may reproduce one feature of a condition while omitting age, comorbidities, prior treatments, environmental factors or chronic progression.
A model can be internally rigorous yet poorly matched to the human question.
Formulation and material equivalence
Sequence, modification, aggregation state, salt or counter-ion, excipients and route can change exposure and response. Clinical evidence for one pharmaceutical preparation does not establish equivalence to separately manufactured research material.
Translation is especially weak when the material used in a cited study is not adequately identified or differs from the material under discussion.
Biomarkers and surrogate endpoints
A biomarker can show that biology changed, but only a validated surrogate can reliably predict a clinical outcome in a defined context. Lowering a laboratory measurement, altering gene expression or changing an imaging signal may not improve how a person feels, functions or survives.
Reproducibility before escalation
Unblinded assessment, small samples, flexible analyses, selective reporting and unstable reagents can inflate early effects. Replication across laboratories, models and experimental conditions helps separate a robust signal from a context-specific or biased result.
Advancing weak evidence does not repair it; later studies may simply expose the original uncertainty at greater cost.
Clinical design can also fail
Even a sound biological hypothesis can be tested poorly in people. Population selection, outcome choice, duration, comparator, adherence, statistical power and operational execution influence whether a trial can answer its question.
A failed trial may challenge the mechanism, the material, the exposure strategy or the trial design. The explanation must come from data rather than being assumed afterward.
Key points
- Mechanism is not outcome.
- Potency is not tissue exposure.
- Target engagement, biomarkers and clinical benefits are distinct steps.
- Species, disease models, formulation and material identity affect translation.
- Reproducibility should precede escalation.
- Human outcome claims require suitable human studies.
What this article does not establish
This article does not predict whether a particular research programme will succeed or establish the safety, effectiveness or human suitability of any AURAPEP material.
References
- Hughes JP, et al. Principles of early drug discovery. Br J Pharmacol. 2011. https://pmc.ncbi.nlm.nih.gov/articles/PMC3058157/
- Fogel DB. Factors associated with clinical trials that fail and opportunities for improving the likelihood of success. Contemp Clin Trials Commun. 2018. https://pmc.ncbi.nlm.nih.gov/articles/PMC6092479/
- Sun D, et al. Why 90% of clinical drug development fails and how to improve it? Acta Pharm Sin B. 2022. https://pubmed.ncbi.nlm.nih.gov/35865092/
- Percie du Sert N, et al. The ARRIVE guidelines 2.0. PLoS Biol. 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7393194/